Andrew Sinclair - Jan 28, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
Director
Signature
/s/ John Heard, as attorney-in-fact
Stock symbol
SRRA
Transactions as of
Jan 28, 2022
Transactions value $
$7,844,617
Form type
4
Date filed
2/1/2022, 04:04 PM
Previous filing
Dec 13, 2021
Next filing
Mar 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock, $0.001 par value Exercise of in-the-money or at-the-money derivative security $3.79M +287K +32.79% $13.20 1.16M Jan 28, 2022 See footnotes F1, F2
transaction SRRA Common Stock, $0.001 par value Purchase $4.05M +150K +12.89% $27.00 1.31M Jan 31, 2022 See footnotes F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Series B Warrants (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -287K -100% $0.00* 0 Jan 28, 2022 Common Stock 287K $13.20 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
F2 An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
F3 Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib.